About IMI

    • The Europain project is funded by the Innovative Medicines Initiative (IMI), a large-scale public-private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA).IMI runs a 2 billion euro research programme aiming to speed up the discovery and development of safer and more effective drugs for patients, and to reinvigorate the biopharmaceutical sector in Europe. IMI supports collaborative research projects that aim to remove hurdles in pharmaceutical R&D, by building partnerships for the exchange of knowledge and expertiseamong large companies and between public and private partners.The main goal of this unique and innovative funding scheme is to improve tools and technologies (such as biomarkers, imaging techniques, knowledge management platforms …) that will enable the faster and more efficient development of safer and better drugs for patients.IMI launches several competitive Calls for proposals a year. The selection of the winning proposals is based on independent peer review and concluded by a Grant Agreement and Project Agreement.


      The research consortia participating in IMI projects include:

      • small- and medium-sized enterprises,
      • universities and other research organisations,
      • hospitals,
      • patients’ organisations,
      • public authorities and
      • large pharmaceutical companies.


      IMI receives € 1 billion funding from the European Commission’s Seventh Framework programme. The EFPIA member companies will match this amount with at least equal in kind contributions (consisting of research related activities and resources).